← All organizations
Highest phase reached
Phase 4
First clinical trial
Jun 1, 2017Last known activity
Apr 8, 2024
Timeline
1920s
- Jan 1, 1924
Kom Op Tegen Kanker— Founded
Drugs by trial phase (25 distinct, 19 trials)
Phase 4 (1 own, 0 via acquisition)
Phase 3 (3 own, 0 via acquisition)
Phase 2 (16 own, 0 via acquisition)
Phase 1 (3 own, 0 via acquisition)
Other trials (2 own, 0 via acquisition)
Indications
Studied for
- Adenocarcinoma
- Adenosarcoma
- Breast Neoplasms
- Carcinoma
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Ovarian Epithelial
- Colonic Neoplasms
- Endometrial Neoplasms
- Head and Neck Neoplasms
- Leiomyosarcoma
- Lung Neoplasms
- Neoplasms
- Osteonecrosis
- Ovarian Neoplasms
- Pancreatic Neoplasms
- Peritoneal Neoplasms
- Sarcoma, Endometrial Stromal
- Sex Cord-Gonadal Stromal Tumors
- Stomach Neoplasms
- Uterine Neoplasms
Recent trials (19)
- NCT06365788CollaboratorPhase 2Apr 8, 2024
- NCT05964361CollaboratorPhase 1/Phase 2Dec 1, 2023
- NCT05872204CollaboratorPhase 2Nov 30, 2023
- NCT05765084CollaboratorPhase 1/Phase 2Feb 24, 2023
- NCT05277766CollaboratorPhase 1Nov 21, 2022
- NCT04911621CollaboratorPhase 1/Phase 2Sep 10, 2021
- NCT04512638CollaboratorPhase 4Oct 1, 2020
- NCT04257461CollaboratorPhase 3Feb 15, 2020
- NCT04168528CollaboratorPhase 1/Phase 2Nov 5, 2019
- NCT04078269CollaboratorPhase 1Aug 26, 2019
- NCT04082182CollaboratorPhase 1Aug 26, 2019
- NCT03924466CollaboratorPhase 2Apr 1, 2019
- NCT03926936CollaboratorPhase 2Mar 13, 2019
- NCT03967938CollaboratorPhase 2Feb 7, 2019
- NCT03779009CollaboratorN/AMar 1, 2018
Details
- Founded
- BE Jan 1, 1924
- Last known activity
- Apr 8, 2024